Bausch + Lomb (BLCO.TO) traded 3.2% higher in U.S. pre-market trading on Wednesday after reporting fourth-quarter adjusted profit and revenue that beat expectations.
Fourth-quarter adjusted profit rose to US$89 million, or US$0.25 per adjusted share, from US$83 million, or US$0.24 per adjusted share in the prior year period. The result beat the FactSet consensus estimate of US$0.23.
Revenue increased 9%, to US$1.28 billion, above the FactSet estimate of US$1.26 billion. The company reported double-digit revenue growth in the contact lens category, and also grew its surgical portfolio across all product categories in the fourth quarter
Bausch + Lomb expects full year 2025 revenue to range between US$4.95 billion to US$5.05 billion. The FactSet estimate is for US$5.02 billion.
"Underpinning our recent success is a commitment to long-term, profitable growth," said Brent Saunders, chairman and CEO, Bausch + Lomb. "Our refocused pipeline is now filled with promise and potential to significantly enhance the standard of care for patients across the spectrum of eye health needs."
The company's shares were last seen up US$0.52, to US$16.87, in New York trading.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。